ABUS
Price
$3.13
Change
-$0.07 (-2.19%)
Updated
Jun 27 closing price
Capitalization
599.48M
31 days until earnings call
KRYS
Price
$138.88
Change
-$3.70 (-2.60%)
Updated
Jun 27 closing price
Capitalization
4.01B
42 days until earnings call
Interact to see
Advertisement

ABUS vs KRYS

Header iconABUS vs KRYS Comparison
Open Charts ABUS vs KRYSBanner chart's image
Arbutus Biopharma
Price$3.13
Change-$0.07 (-2.19%)
Volume$1.84M
Capitalization599.48M
Krystal Biotech
Price$138.88
Change-$3.70 (-2.60%)
Volume$418.51K
Capitalization4.01B
ABUS vs KRYS Comparison Chart in %
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. KRYS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Buy and KRYS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ABUS: $3.13 vs. KRYS: $138.88)
Brand notoriety: ABUS and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 225% vs. KRYS: 112%
Market capitalization -- ABUS: $599.48M vs. KRYS: $4.01B
ABUS [@Biotechnology] is valued at $599.48M. KRYS’s [@Biotechnology] market capitalization is $4.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 6 TA indicator(s) are bullish while KRYS’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 6 bullish, 4 bearish.
  • KRYS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than KRYS.

Price Growth

ABUS (@Biotechnology) experienced а -8.75% price change this week, while KRYS (@Biotechnology) price change was +4.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ABUS is expected to report earnings on Jul 31, 2025.

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.01B) has a higher market cap than ABUS($599M). ABUS YTD gains are higher at: -4.281 vs. KRYS (-11.349). KRYS has higher annual earnings (EBITDA): 140M vs. ABUS (-75.1M). KRYS has more cash in the bank: 617M vs. ABUS (113M). ABUS has less debt than KRYS: ABUS (1.19M) vs KRYS (9.66M). KRYS has higher revenues than ABUS: KRYS (333M) vs ABUS (6.4M).
ABUSKRYSABUS / KRYS
Capitalization599M4.01B15%
EBITDA-75.1M140M-54%
Gain YTD-4.281-11.34938%
P/E RatioN/A33.30-
Revenue6.4M333M2%
Total Cash113M617M18%
Total Debt1.19M9.66M12%
FUNDAMENTALS RATINGS
ABUS vs KRYS: Fundamental Ratings
ABUS
KRYS
OUTLOOK RATING
1..100
5039
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
7941
SMR RATING
1..100
9857
PRICE GROWTH RATING
1..100
6262
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (66) in the Biotechnology industry is in the same range as KRYS (71) in the Pharmaceuticals Major industry. This means that ABUS’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABUS (79) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than ABUS’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABUS (98) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than ABUS’s over the last 12 months.

KRYS's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as ABUS (62) in the Biotechnology industry. This means that KRYS’s stock grew similarly to ABUS’s over the last 12 months.

KRYS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as ABUS (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSKRYS
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
86%
Momentum
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
81%
MACD
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 21 days ago
78%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 14 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
80%
Aroon
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DURAX14.210.14
+1.00%
DWS ESG International Core Eq A
HGOYX78.100.66
+0.85%
Hartford Growth Opportunities Y
BUIEX57.350.42
+0.74%
Buffalo Blue Chip Growth Instl Cl
GCVIX23.900.03
+0.13%
Goldman Sachs Large Cp Val Insghts Instl
VSCCX14.840.01
+0.07%
JPMorgan Small Cap Blend C

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-2.19%
IDYA - ABUS
46%
Loosely correlated
-4.13%
DNLI - ABUS
43%
Loosely correlated
-2.69%
IMVT - ABUS
43%
Loosely correlated
-1.77%
KRYS - ABUS
42%
Loosely correlated
-2.60%
TERN - ABUS
42%
Loosely correlated
-4.25%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-2.60%
XNCR - KRYS
54%
Loosely correlated
-3.10%
IDYA - KRYS
54%
Loosely correlated
-4.13%
CRNX - KRYS
54%
Loosely correlated
-0.10%
ACLX - KRYS
54%
Loosely correlated
+0.90%
CGON - KRYS
54%
Loosely correlated
-0.46%
More